City of Hope reveals its bold vision to invest more than $1 billion for world-class cancer care at FivePoint Gateway in Orange County, California. They will accelerate plans to bring highly specialized cancer care, phase I-III clinical trials, and precision medicine and early detection to the nations most sixth populous county.
Key take ways from this important news:
- In collaboration with FivePoint Holdings (LLC (NYSE: FPH), an owner and developer of mixed-use, master-planned communities in California, City of Hope is planning to purchase approximately 11 acres of land—including a building of approximately 190,000 square feet—at FivePoint Gateway in Irvine, California, for its cancer campus expected to open 2021.
- The state-of-the-art comprehensive cancer campus is expected to include an outpatient center, a clinical research center with access to phase I-III clinical trials, integrated cancer preventative care utilizing emerging technologies and Orange County’s only specialty hospital focused exclusively on treating and curing cancer.
- Evolution in strategy speeds City of Hope’s unparalleled care, scientific breakthroughs and new treatments to a community with growing needs.
About City of Hope
A private, not-for-profit clinical research center, hospital and graduate medical school located in Duarte, California. The center’s main campus resides on 110 acres of land adjacent to boundaries of Duarte and Irwindale, with a network of clinical practice locations throughout Southern California, satellite offices in Monrovia and Irwindale, and regional fundraising offices throughout the United States.
They are best known as a cancer treatment center. It has been designated as a Comprehensive Cancer Center by the National Cancer Institute. City of Hope has also been ranked one of the nation’s Best Cancer Hospitals by U.S. News & World Report for over 10 years and is a founding member of the National Comprehensive Cancer Network.
City of Hope played a role in the development of synthetic human insulin in 1978. The center has performed 13,000 hematopoietic stem cell transplants as of 2016, with patient outcomes that consistently exceed the national averages.